Search results
Results from the WOW.Com Content Network
Jun. 14—EL PASO — In honor of World Elder Abuse Awareness Day on June 15, the FBI wants to remind friends, family, and loved ones of elderly Americans to know the signs of elder fraud. While ...
The FBI’s Internet Crime Complaint Center, which compiles information about and investigates online fraud, noted an 11% increase in elder fraud cases between 2022 and 2023. Americans over 60 ...
The FBI-Boston reports that the most common elder fraud schemes reported to IC3.gov in 2023 were "tech support scams, confidence and romance scams, investment scams, and government impersonation ...
1,076 incidents per year resulting in $2.6 billion in losses Based on only fraud reported in the press. The report acknowledges that making an estimate based only on press reports will produce an underestimate by a factor of five, though other estimates suggest it may be closer to a factor of forty. Federal Trade Commission [14] 2007
Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud, off-label promotion, and inadequate manufacturing practices. [ 3 ] [ 4 ] With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act ...
The problem began in 2012, when the process for making tetrazole, a chemical intermediate in the production of various angiotensin II inhibitor medications for hypertension (popularly known by their common drug name suffix "sartan") was changed by generic drug manufacturers in favor of several cheaper and more efficient processes.
People over the age of 60 in the US reportedly lost more than $3.4 billion in fraud schemes in 2023, a nearly 11% increase from the year before, according to a report from the FBI released Tuesday.
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.